TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases
US10987319B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2019 |
| Grant date | Apr 27, 2021 |
| Priority date | — |
| Expiry date | Jun 28, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of use of a composition comprising an autophagy enhancement compound for treating neurodegenerative diseases. In particular, the said composition is used to treat the neural condition of synaptic dysfunction. Such neurodegenerative diseases include Parkinson's disease, Alzheimer's disease, Huntington's disease, Frontotemporal dementia with parkinsonism-17 (FTDP-17), Pick disease (PiD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD) and Cerebral amyloid angiopathy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.